title: Cost-effectiveness of vaccination against herpes zoster.
abstract: Herpes zoster (HZ) is a common disease among elderly, which may develop into a severe pain syndrome labeled postherpetic neuralgia (PHN). A live-attenuated varicella zoster virus vaccine has been shown to be effective in reducing the incidence and burden of illness of HZ and PHN, providing the opportunity to prevent significant health-related and financial consequences of HZ. In this review, we summarize the available literature on cost-effectiveness of HZ vaccination and discuss critical parameters for cost-effectiveness results. A search in PubMed and EMBASE was performed to identify full cost-effectiveness studies published before April 2013. Fourteen cost-effectiveness studies were included, all performed in western countries. All studies evaluated cost-effectiveness among elderly above 50 years and used costs per quality-adjusted life year (QALY) gained as primary outcome. The vast majority of studies showed vaccination of 60- to 75-year-old individuals to be cost-effective, when duration of vaccine efficacy was longer than 10 years. Duration of vaccine efficacy, vaccine price, HZ incidence, HZ incidence and discount rates were influential to the incremental cost-effectiveness ratio (ICER). HZ vaccination may be a worthwhile intervention from a cost-effectiveness point of view. More extensive reporting on methodology and more detailed results of sensitivity analyses would be desirable to address uncertainty and to guarantee optimal comparability between studies, for example regarding model structure, discounting, vaccine characteristics and loss of quality of life due to HZ and PHN.
authors.affiliation: a Unit of PharmacoEpidemiology & PharmacoEconomics (PE2); Department of Pharmacy; University of Groningen; The Netherlands.
authors.forename: Pieter T
authors.initials: PT
authors.lastname: de Boer
authors.forename: Jan C
authors.initials: JC
authors.lastname: Wilschut
authors.forename: Maarten J
authors.initials: MJ
authors.lastname: Postma
mesh_terms: D003362:Cost-Benefit Analysis; D006562:Herpes Zoster / Q000191:economics* / Q000276:immunology / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology*; D006801:Humans; D051474:Neuralgia, Postherpetic / Q000191:economics* / Q000276:immunology / Q000517:prevention & control*; D019057:Quality-Adjusted Life Years; D014611:Vaccination / Q000191:economics* / Q000379:methods
chemical_list: D053061:Herpes Zoster Vaccine
keywords: cost-effectiveness; herpes zoster; postherpetic neuralgia; shingles; vaccination; vaccine; zostavax